Johnson and Johnson Merck Consumer Pharmaceuticals News

Johnson & Johnson : We're Creaming Medivation, Inc. , Boehringer Ingelheim Corporation , Bristol-Myers Squibb Company and Pfizer Inc.

Johnson & Johnson expects to file for Food and Drug Administration approval of more than 10 new drugs over the next four years, the drug maker said Thursday.

Shares of Johnson & Johnson have been in a solid uptrend throughout 2013. As shown in the chart below, the stock looks extended now, so investors should wait for a pullback.

Linked here is a detailed quantitative analysis of Johnson & Johnson . Below are some highlights from the above linked analysis: Company Description: Johnson & Johnson is a leader in the pharmaceutical, medical device and consumer products industries.

Health-care giant Johnson & Johnson plans to seek approval for 10 new treatments to combat cancer, Hepatitis C, schizophrenia and influenza over the next four years, the company said Thursday.

BIG PLANS: Johnson & Johnson says it's poised by 2017 to seek regulatory approval for a dozen new medicines and two dozen variations of existing ones.

Johnson & Johnson said its pharmaceutical unit plans to submit more than 10 new-product applications by 2017, as the health-care heavyweight hopes to build on the division's turnaround in recent years.

The firm set an "underperform" rating on the stock. A number of other firms have also recently commented on JNJ.

Johnson & Johnson says it plans to submit more than 10 new treatments to regulators for approval and 25 applications for additional uses of approved drugs by 2017.

In Part I of "Johnson & Johnson: At The Crossroads", it was determined that a dividend growth rate of 8.2% was sustainable for at least the next 15 years even if net income growth rate remained around the projected 6%. In Part II , it was determined that Johnson & Johnson had sufficient investable funds available at the end of 2012 to increase its ... (more)

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! In the wake of scandals and investigations over manufacturing gaffes, countless product recalls and questionable marketing practices, Johnson & Johnson is embarking on a round of corporate soul searching.

During the second half of the 20th century, there was a small handful of blue-chip stocks that served as a "secret handshake" of sorts among those steeped in dividend investing.

Hedge funds' returns have stayed "lackluster" this year, with the $2.3 trillion industry trailing the gains of the Standard & Poor's 500 Index by about 10 percentage points, according to Goldman Sachs Group Inc.

Meena is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.

Atlantic City's $2.4 billion Revel casino formally completed its financial restructuring and emerged from Chapter 11 bankruptcy Tuesday.

The firm is actively filing DePuy ASR lawsuits on behalf of those who allegedly suffered metallosis, premature device failure, or other serious complications related to the 2010 DePuy ASR recall.

A friend went into a kids hair salon and was asking about shampoo. The beautician said that there was a recent show on 20/20 or etc.

You will find a comprehensive dividend stock analysis of Johnson & Johnson in this article .

Though Janssen Korea says it is confident it will resolve its manufacturing issues, product recall and suspensions could be followed by lawsuits and imprisonment.

The study saw more than 400 patient groups from 39 different countries assessing 30 'medtech' companies on their ability to meet patient expectations.